N Katakami1, T Harada2, T Murata3, K Shinozaki4, M Tsutsumi5, T Yokota6, M Arai6, Y Tada6, M Narabayashi7, N Boku8. 1. Kobe City Medical Center General Hospital, Kobe, Japan. 2. Center for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Japan. 3. Department of Breast Oncology, Aichi Cancer Center Aichi Hospital, Okazaki, Japan. 4. Department of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan. 5. Department of Urology, Hitachi General Hospital, Hitachi, Japan. 6. Global Development,Shionogi & Co., Ltd., Osaka, Japan. 7. Department of Palliative Therapy, Cancer Institute Hospital of JFCR, Tokyo, Japan. 8. Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Abstract
Background: The efficacy and safety of naldemedine (a peripherally-acting µ-opioid receptor antagonist) for opioid-induced constipation (OIC) in subjects with cancer was demonstrated in the primary report of a phase 3, double-blind study (COMPOSE-4) and its open-label extension (COMPOSE-5). The primary endpoint, the proportion of spontaneous bowel movement (SBM) responders, was met. Here, we report results from secondary endpoints including quality of life (QOL) assessments from these studies. Patients and methods: In COMPOSE-4, eligible adults with OIC and cancer were randomly assigned 1:1 to receive once-daily oral naldemedine 0.2 mg (n=97) or placebo (n=96) for 2 weeks, and those who continued on to COMPOSE-5 received naldemedine for 12 weeks (n=131). Secondary assessments in COMPOSE-4 included the proportion of complete SBM (CSBM) responders, SBM or CSBM responders by week, and subjects with ≥1 SBM or CSBM within 24 hours post-initial dose. Changes from baseline in the frequency of SBMs or CSBMs per week were assessed at Week 1 and Week 2. Time to the first SBM or CSBM post-initial dose was also evaluated. In both studies, QOL impact was evaluated by Patient Assessment of Constipation-Symptoms (PAC-SYM) and PAC-QOL questionnaires. Results:Naldemedine improved bowel function for all secondary efficacy assessments vs placebo (all P≤0.0002). The timely onset of naldemedine activity vs placebo was evidenced by median time to the first SBM (4.7 vs 26.6 hours) and CSBM (24.0 vs 218.5 hours) post-initial dose (all P<0.0001). In COMPOSE-4, significant differences between groups were observed with the PAC-SYM stool domain (P=0.045) and PAC-QOL dissatisfaction domain (P=0.015). In COMPOSE-5, naldemedine significantly improved overall and individual domain scores of PAC-SYM and PAC-QOL from baseline (all P≤0.03). Conclusions: Naldemedine provided effective and timely symptomatic relief from OIC and improved the QOL of subjects with OIC and cancer. Trial registration ID: www.ClinicalTrials.jp: JAPIC-CTI-132340 (COMPOSE-4) and JAPIC-CTI-132342 (COMPOSE-5).
RCT Entities:
Background: The efficacy and safety of naldemedine (a peripherally-acting µ-opioid receptor antagonist) for opioid-induced constipation (OIC) in subjects with cancer was demonstrated in the primary report of a phase 3, double-blind study (COMPOSE-4) and its open-label extension (COMPOSE-5). The primary endpoint, the proportion of spontaneous bowel movement (SBM) responders, was met. Here, we report results from secondary endpoints including quality of life (QOL) assessments from these studies. Patients and methods: In COMPOSE-4, eligible adults with OIC and cancer were randomly assigned 1:1 to receive once-daily oral naldemedine 0.2 mg (n=97) or placebo (n=96) for 2 weeks, and those who continued on to COMPOSE-5 received naldemedine for 12 weeks (n=131). Secondary assessments in COMPOSE-4 included the proportion of complete SBM (CSBM) responders, SBM or CSBM responders by week, and subjects with ≥1 SBM or CSBM within 24 hours post-initial dose. Changes from baseline in the frequency of SBMs or CSBMs per week were assessed at Week 1 and Week 2. Time to the first SBM or CSBM post-initial dose was also evaluated. In both studies, QOL impact was evaluated by Patient Assessment of Constipation-Symptoms (PAC-SYM) and PAC-QOL questionnaires. Results: Naldemedine improved bowel function for all secondary efficacy assessments vs placebo (all P≤0.0002). The timely onset of naldemedine activity vs placebo was evidenced by median time to the first SBM (4.7 vs 26.6 hours) and CSBM (24.0 vs 218.5 hours) post-initial dose (all P<0.0001). In COMPOSE-4, significant differences between groups were observed with the PAC-SYM stool domain (P=0.045) and PAC-QOL dissatisfaction domain (P=0.015). In COMPOSE-5, naldemedine significantly improved overall and individual domain scores of PAC-SYM and PAC-QOL from baseline (all P≤0.03). Conclusions: Naldemedine provided effective and timely symptomatic relief from OIC and improved the QOL of subjects with OIC and cancer. Trial registration ID: www.ClinicalTrials.jp: JAPIC-CTI-132340 (COMPOSE-4) and JAPIC-CTI-132342 (COMPOSE-5).
Authors: Augusto Caraceni; Geoffrey Hanks; Stein Kaasa; Michael I Bennett; Cinzia Brunelli; Nathan Cherny; Ola Dale; Franco De Conno; Marie Fallon; Magdi Hanna; Dagny Faksvåg Haugen; Gitte Juhl; Samuel King; Pål Klepstad; Eivor A Laugsand; Marco Maltoni; Sebastiano Mercadante; Maria Nabal; Alessandra Pigni; Lukas Radbruch; Colette Reid; Per Sjogren; Patrick C Stone; Davide Tassinari; Giovambattista Zeppetella Journal: Lancet Oncol Date: 2012-02 Impact factor: 41.316
Authors: M Camilleri; D A Drossman; G Becker; L R Webster; A N Davies; G M Mawe Journal: Neurogastroenterol Motil Date: 2014-08-28 Impact factor: 3.598
Authors: Karin S Coyne; Chris Sexton; Robert J LoCasale; Frederic R King; Mary Kay Margolis; Sam H Ahmedzai Journal: Front Oncol Date: 2016-06-08 Impact factor: 6.244